Roswell Park spin­out rais­es $35M from Chi­nese in­vestors to pur­sue one-two punch for adop­tive T cell ther­a­py

Amid buzzing re­ports out of ASH track­ing var­i­ous im­munother­a­pies’ suc­cess in treat­ing blood can­cers, a Buf­fa­lo-based biotech has qui­et­ly bagged its first ven­ture round to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER